Kimberly Freeman
Vice President of Commercial PlanningMs. Kimberly Freeman served as Vice President of Commercial Planning at Adaptimmune Therapeutics plc. She wasChief Strategy Officer at Zentalis Pharmaceuticals, Inc. from August 2023 until 2025. Ms. Freeman joins Zentalis with clinical development and strategic leadership experience, including deep expertise in oncology, particularly in gynecologic malignancies and the DNA damage response (DDR) pathway. Prior to joining Zentalis, Ms. Freeman was Vice President, US Head of DDR Franchise, Oncology at AstraZeneca. She was responsible for overseeing the strategic direction and cross-functional efforts for LYNPARZA (olaparib) and other therapies targeting the DDR pathway, which is an important hallmark in ovarian and other cancers. Previously, she held various leadership roles at biopharmaceutical companies including Adaptimmune, Boehringer Ingelheim and GlaxoSmithKline. After receiving her Bachelor of Science in Biology from Cornell University, Ms. Freeman was a Research Scientist in the Department of Hematology/Medical Oncology at Weill Cornell Medical Center and later pursued Graduate Studies at SUNY Upstate Medical Center. Ms. Freeman also received Finance and Marketing Certificates from the Wharton School of the University of Pennsylvania.
Positions
- Company NameAdaptimmune Therapeutics plcStock CodeADAPYPositionVice President of Commercial PlanningColleagues
- CJChristopher James HillCEO, CFO, Secretary & Director
- LMLawrence M. AllevaIndependent Non-Executive Chairman
- HKHelen Katrina Tayton-MartinCo-Founder
- JPJuli P. MillerVP of Corporate Affairs & Investor Relations
- DLDana LynchSenior Director of Corporate Communications
- MKMalcolm K. BrennerMember of the Scientific Advisory Board
- SAStephan A. GruppMember of the Scientific Advisory Board
- TGThomas GajewskiMember of the Scientific Advisory Board
